Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

CORONARY STENTS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Coronary Stents in US$ Million and Thousand Units by the following Product Segments: Bare Metal Stents, and Drug Eluting Stents. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 62 companies including many key and niche players such as Angiotech Pharmaceuticals, Abbott Vascular, Biosensors International, Boston Scientific Corp., Cordis Corporation, Medtronic, Inc., Medtronic Cardiovascular, Inc., OrbusNeich, and Terumo Europe N.V. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1148
Price : $4500
Companies : 62
Pages : 440
Date : October 2011
Market Data Tables : 171
Status: * New Report

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  CORONARY STENTS (Complete Report) Pages : 440   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......14 $295  
   Study Reliability and Reporting Limitations.......1  
   Disclaimers.......2  
   Data Interpretation & Reporting Level.......3
Quantitative Techniques & Analytics.......3
Product Definitions and Scope of Study.......3
Bare Metal Stents.......3
  
   Drug Eluting Stents.......4  
  2. GLOBAL MARKET OVERVIEW.......54 $395  
   Growth Revives as Drug Eluting Stents Bounce Back.......5
What’s Next on Cards in Coronary Stent Market?.......5
1$100
   Market Snapshots.......61$100
   Current and Future Analysis.......7
Drug Eluting Stents Steal the Show.......7
1$100
   Star Player J&J to Quit DES Business in an Expensive Market Withdrawal.......81$100
  3. MARKET TRENDS AND ISSUES.......94 $395  
   Drug Eluting Stent System – Safety Concerns.......9
Declining Prices – A Major Concern.......9
Restenosis - the Real Growth Driver.......9
1$100
   Small Vessels – A Major Cause of Restenosis.......10
Aging Population Propels Coronary Stent Market.......10
Next Generation Stents – A Boon for Treating Coronary Diseases.......10
1$100
   Direct Stenting Systems Spur Growth.......11
Drug Choice Impacts Market Entry.......11
Threats to Coronary Stents – Alternative Therapies/Devices.......11
Cell Transplantation – A Major Threat to Coronary Stents.......11
1$100
   Coronary Stents Market Challenged by Drug Therapy.......121$100
  4. COMPETITIVE ANALYSIS.......133 $595  
   Coronary Stents – Leading Players.......13
Table 1: Leading Players in the Global Coronary Stents Market (2010 & 2012) – Percentage Breakdown of Market Share by Company - Boston Scientific, Abbott (Guidant), Johnson & Johnson, Medtronic, and Others (includes corresponding Graph/Chart).......13
1$350
   Bare Metal Stents – Leading Players.......14
Table 2: Leading Players in the Global Bare Metal Stents Market (2010) – Percentage Breakdown of Share for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart).......14
Drug-Eluting Stents – Leading Players.......14
Table 3: Global Drug Eluting Stents Market (2010): Percentage Breakdown of Share by Company - Boston Scientific, Abbott Labs, Johnson and Johnson, Medtronic, Others (includes corresponding Graph/Chart).......14
Major DES Types in the Market and Leading Manufacturers.......14
1$350
   Comparative Analysis of the Leading Players.......151$100
  5. CORONARY DISEASE - A PERSPECTIVE.......166 $495  
   Factors Responsible for Coronary Diseases.......16
Controllable Risk Factors.......16
High Blood Cholesterol.......16
Sedentary Life Style and Habits.......16
1$100
   Smoking Habits.......17
High Blood Pressure.......17
Uncontrollable Risk Factors.......17
Age.......17
Heredity.......17
Gender.......17
Causative Risk Factors.......17
1$100
   Stress and Anger.......18
Obesity.......18
Diabetes.......18
Symptoms of Coronary Artery Disease.......18
Diagnosis.......18
1$100
   Treatment.......19
Drug Supported Treatments.......19
Invasive Treatments.......19
Bypass Surgery.......19
Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty).......19
1$100
   Natural Therapy.......20
Coronary Angioplasty Suitable for Acute Myocardial Infarction.......20
Advancements in Coronary Disease Treatment Modalities.......20
University of Virginia’s Microbe Solution for Post Surgical Complications.......20
1$100
   Radiation for Re-clogged Arteries Show Promise.......21
Radioactive Coronary Stents Promise Bright Future.......21
1$100
  6. CORONARY STENTS - PRODUCT OVERVIEW.......228 $595  
   Introduction.......22
Evolution of Coronary Stents.......22
Applications of Coronary Stents.......22
1$100
   Stent Deployment.......231$100
   Key Stent Delivery Platforms by Select Company.......24
Coronary Stent Designs.......24
Key Factors Determining Coronary Stent Performance.......24
Delivery Convenience.......24
Efficient Scaffolding.......24
1$100
   Radiopacity (Visibility).......25
Optimum Flexibility.......25
Shape Conformability.......25
Material for Coronary Stent.......25
Risk Associated with Stenting.......25
1$100
   Improper Stent Implantation Likely Cause for In-Stent Restenosis.......261$100
   Precautions.......27
Direct Coronary Stenting – Creating an Enliven.......27
Limitations.......27
1$100
   Regulatory Approvals Wooing Stent Market.......28
A Peek into Regulatory Approvals for Coronary Stents.......28
2$200
  7. PRODUCT SEGMENTS.......305 $395  
   Bare Metal Stents.......30
Major Bare Metal Stents by Company.......30
Drug-Eluting Stents.......30
1$100
   DE Stents Overshadow Intravascular Brachytherapy Interventions.......31
Major Drug-Eluting Stents by Company.......31
Drugs for Coating DESs.......31
1$100
   Cytotoxic or Cytostatic Drug – the Debate Continues.......32
Dosing and Deliverability Crucial for DES.......32
Polymer Coatings for Effective Dosing and Deliverability.......32
Drugs Used for DES by Major Competitors in the Stent Market.......32
1$100
   Leading Coronary Stent Brands.......33
Cypher.......33
Structure and Delivery Mechanism.......33
1$100
   Taxus.......34
Structure and Delivery Mechanism.......34
1$100
  8. RESEARCH AND DEVELOPMENT.......35   
   Extensive R&D Underway in Global Drug-Eluting Stents Market.......35
At the Labs.......35
Other Products Under Trials – A Recent Past Perspective.......35
OMT Developing R-stent.......35
Reva Developing Stainless Steel Bare-Metal Stent.......35
1$100
   D&P Corp Developing Bovine Pericardium- Covered Stent.......36
Advanced Bio Synthesizing Porous Drug-Eluting Stents.......36
Lombard Medical Developing PEP Coatings.......36
Shiga Develops Biodegradable Drug-Eluting Stent.......36
1$100
  9. PRODUCT INNOVATIONS/INTRODUCTIONS.......375 $395  
   Boston Scientific Launches ION™ Platinum Chromium Stent System.......37
Terumo Introduces Nobori Drug-Eluting Coronary Stent.......37
Boston Scientific Unveils TAXUS® Element™ and PROMUS® Element™ Stent Systems.......37
1$100
   Covidien Introduces EverFlex+™ Self-Expanding Peripheral Stent System.......38
Boston Scientific Launches Taxus Element Stent System in European Union.......38
Cordis Introduces PRESILLION™ PLUS Stent System in Europe.......38
Medtronic Launches Resolute Integrity Stent System.......38
1$100
   InspireMD Unveils MGuard Prime.......39
Boston Scientific Introduces Taxus Eluting Stent System.......39
Boston Scientific Unveils TAXUS Liberte Paclitaxel Eluting Stent System in
  Japan.......39
Alvimedica Launches Coracto Drug-Eluting Stent in Europe.......39
1$100
   Abbott Labs to Launch XIENCE V in China.......40
Medtronic Launches Driver Sprint RX Coronary STENT System.......40
Existent Introduces Premier Coronary Stent System.......40
Medtronic to Unveil Balloon Catheter Systems and Coronary Stents.......40
NanoInterventions Launches Mouse Stent Model.......40
1$100
   InspireMD - MGuard™ Coronary Stent Launched in Italy.......41
CeloNova BioSciences Launches CATANIA™ Coronary Stent with NanoThin
  Polyzene®-F.......41
Angiotech Launches Cook Medical’s Drug Eluting Zilver® PTX™ Stent in New
  Zealand.......41
1$100
  10. RECENT INDUSTRY ACTIVITY.......4212 $950  
   Boston Scientific Receives FDA Approval for Novel Paclitaxel-Eluting Coronary
  Stent.......42
Boston Scientific Receives Approval for Distribution of PROMUS® Everolimus-Eluting
  Stent.......42
Cordis Discontinues Production of NEVO™ Sirolimus- Eluting Coronary Stents.......42
1$100
   Boston Scientific Receives FDA Approval for ION Stent.......43
Abbott Obtains FDA Approval to Extend RX ACCULINK® Carotid Stent System
  Application.......43
Boston Scientific Receives CE Mark Approval for OMEGA™ Platinum Chromium Stent
  System.......43
1$100
   Stentys Launches Stents across Additional Countries in Europe.......44
Opto Circuits Acquires N.S. Remedies.......44
Biosensors International Group Takes Over Assets of Devax.......44
Cordis Signs Distribution Agreement with Ostial Solutions.......44
Medtronic Obtains FDA Approval for Integrity Coronary Stent System.......44
1$100
   Boston Scientific Receives Approval from Japanese MHLW for PROMUS® Coronary
  Stent.......45
InspireMD Selects Kirloskar Technologies for Distributing Coronary Stent
  Systems.......45
Boston Scientific Expands PROMUS® Everolimus-Eluting Coronary Stent System.......45
1$100
   Boston Scientific Receives TGS Approval from Australia.......46
Svelte Medical Systems Commences Clinical Trial of SOAW Delivery System.......46
Abbott Receives Japan's MHLW Approval for Xience V.......46
Opto Circuits Receives Mark Approval from Communite European.......46
Abbott Receives Health Canada Approval for XIENCE V® Stent System.......46
1$100
   Medtronic Secures Japan's MHLW Approval for Endeavor® Drug Eluting Stent.......47
Boston Scientific Takes Over Labcoat.......47
Micell and Maxcor Sign Strategic Agreement.......47
Cordis Receives FDA Approval for Variant of Cypher Sirolimus-Eluting Coronary
  Stent.......47
Boston Scientific Obtains CE Mark Approval for Promus Element Everolimus-Eluting
  Coronary Stent System.......47
1$100
   Cypher Select® Plus Sirolimus-eluting Coronary Stent Gains CE Mark for Treatment in
  Diabetic Patients.......48
Atrium Medical Obtains CE Mark for Cinatra™.......48
Medtronic Secures CE Mark Approval for Endeavor Drug-Eluting Stent for Use in Treatment
  of ACS.......48
CorNova® Obtains CE mark approval for Valecor Platinum Coronary Stent System.......48
1$100
   Cook Medical Receives CE Mark Approval and Launches Zilver® PTX® Drug-Eluting
  Peripheral Stent.......49
Disa Receives CE Approval for Coronary Stent.......49
Datascope Acquires Peripheral Stent Business of Sorin Group.......49
Boston Scientific Receives FDA approval for TAXUS® Liberte® Drug-Eluting STENT.......49
Abbott Labs Receives FDA Approval for Xience V.......49
1$100
   Bard to Purchase Assets of LifeStent Product Portfolio.......50
Medtronic Receives the US FDA Approval to Use Endeavor® Stent.......50
Medtronic Inc. Receives Approval for its Drug-Eluting Stent, “Endeavor” In
  Canada.......50
Boston Scientific to Market TAXUS® Liberte® Stent System in Canada.......50
1$100
   Abbott Applies for Approval of XIENCE™ V in Japan.......51
Medinol Achieves CE Mark Approval for Presillion™ Cobalt Chromium Coronary Stent
  System.......51
Iberhospitex Receives Spanish Approval to Sell Palau Pharma’s “Active” Coronary
  Stent.......51
Clearstream’s Intrepide Drug Eluting Stent of Clearstream Receives CE mark
  approval.......51
1$100
   Terumo Introduces Its Drug-Eluting Stent in Germany and Marks Its European
  Entry.......52
Tryton Medical’s Side-Branch Stent Achieves CE Mark Approval.......52
CV Therapeutics Offers its Stent Coating Technology to Medlogics Device
  Corporation.......52
Abbott’s 2.25mm-Sized XIENCE™ V Drug Eluting Stent receives CE Mark of
  Approval.......52
1$100
   Biosensors Receives CE Mark Approval for BioMatrix® Stent System.......53
Nfocus Neuromedical’s CardioVasc™ Stent-Graft and Delivery System Receives CE Mark
  Approval.......53
1$100
  11. FOCUS ON SELECT GLOBAL PLAYERS.......543 $295  
   Angiotech Pharmaceuticals (Canada).......54
Abbott Vascular (USA).......54
Biosensors International (USA).......54
1$100
   Boston Scientific Corp. (USA).......55
Cordis Corporation (JNJ) - (USA).......55
1$100
   Medtronic, Inc. (USA).......56
Medtronic Cardiovascular, Inc. (USA).......56
OrbusNeich (Hong Kong).......56
Terumo Europe N.V. (Belgium).......56
1$100
  12. GLOBAL MARKET PERSPECTIVE.......57   
   Table 4: World Recent Past, Current & Future Analysis for Coronary Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......571$350
   Table 5: World Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......581$350
   Table 6: World Historic Review for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......591$350
   Table 7: World Historic Review for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart).......601$350
   Table 8: World 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......611$350
   Table 9: World 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......621$350
   Table 10: World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......631$350
   Table 11: World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment–Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......641$350
   Table 12: World Historic Review for Coronary Stents by Product Segment–Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......651$350
   Table 13: World Historic Review for Coronary Stents by Product Segment–Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart).......661$350
   Table 14: World 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......671$350
   Table 15: World 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......681$350
   Table 16: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......691$350
   Table 17: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......701$350
   Table 18: World Historic Review for Bare Metal Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sale sin US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart).......711$350
   Table 19: World Historic Review for Bare Metal Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart).......721$350
   Table 20: World 15-Year Perspective for Bare Metal Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......731$350
   Table 21: World 15-Year Perspective for Bare Metal Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......741$350
   Table 22: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......751$350
   Table 23: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2009 through 2017 (includes corresponding Graph/Chart).......761$350
   Table 24: World Historic Review for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......771$350
   Table 25: World Historic Review for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart).......781$350
   Table 26: World 15-Year Perspective for Drug Eluting Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......791$350
   Table 27: World 15-Year Perspective for Drug Eluting Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......801$350
  13. THE UNITED STATES.......819 $2450  
   A. Market Analysis.......81
Largest Market Worldwide.......81
Coronary Artery Disease - A US Perspective.......81
Baby Boomers Boost Coronary Stent Market.......81
Revival in the DES Market.......81
1$100
   Reimbursement System.......82
National Average Medicare Payment For DRGS.......82
Competitive Scenario.......82
Leading Players.......82
Coronary Stents – Boston Scientific and JNJ Battle for Dominance.......82
1$100
   Table 28: Leading Players in the US Coronary Stents Market (2010) – Percentage Breakdown of Share for Boston Scientific, Abbott and Johnson & Johnson (includes corresponding Graph/Chart).......83
Drug Eluting Stents – Competition in the Brewing.......83
Table 29: Leading Players in the US Drug-Eluting Stents Market (2010) – Percentage Breakdown of share for Boston Scientific, Abbott Labs, J&J-Cordis and Medtronic (includes corresponding Graph/Chart).......83
1$350
   Regulatory Environment.......84
B. Market Analytics.......84
Table 30: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......84
1$350
   Table 31: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......851$350
   Table 32: US Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......861$350
   Table 33: US Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......871$350
   Table 34: US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......881$350
   Table 35: US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......891$350
  14. JAPAN.......909 $2950  
   A. Market Analysis.......90
Prospects Weighed down by Regulatory Entanglements.......90
Japanese Coronary Stents Command Higher Prices.......90
Table 36: Coronary Stent Pricing (2008): Comparative Analysis of Prices in Japan, US, Europe and Global Average (includes corresponding Graph/Chart).......90
1$350
   Competitive Landscape.......91
Table 37: Leading Players in the Japanese Coronary Stent Market ( 2010) – Percentage Breakdown of Share for Johnson & Johnson, Medtronic, Boston Scientific, and Others (includes corresponding Graph/Chart).......91
1$350
   Table 38: Leading Players in the Japanese Bare Metal Stent Market (2010) – Percentage Breakdown by of Share for Medtronic, Boston Scientific, JNJ and Others (includes corresponding Graph/Chart).......92

Table 39: Leading Players in Japanese Drug-Eluting Stent Market (2010) – Percentage Breakdown of Share for Johnson & Johnson and Boston Scientific (includes corresponding Graph/Chart).......92
1$350
   B. Market Analytics.......93
Table 40: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......93
1$350
   Table 41: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......941$350
   Table 42: Japanese Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......951$350
   Table 43: Japanese Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......961$350
   Table 44: Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......971$350
   Table 45: Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......981$350
  15. EUROPE.......9915 $3950  
   A. Market Analysis.......99
Cardiovascular Disease in Europe – A Perspective.......99
Growth Bar Too Low.......99
Two-Speed Europe.......99
1$100
   Stent Market’s Merger Mania.......100
Dampeners to Rapid Adoption of DES in Europe.......100
1$100
   Competitive Scenario.......101
Table 46: Leading Players in the European Drug- Eluting Stent Market (2010) – Percentage Breakdown of Share for Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart).......101
1$350
   B. Market Analytics.......102
Table 47: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......102
1$350
   Table 48: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years2009 through 2017 (includes corresponding Graph/Chart).......1031$350
   Table 49: European Historic Review for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1041$350
   Table 50: European Historic Review for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1051$350
   Table 51: European 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1061$350
   Table 52: European 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Unit Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2075 (includes corresponding Graph/Chart).......1071$350
   Table 53: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......1081$350
   Table 54: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1091$350
   Table 55: European Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1101$350
   Table 56: European Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1111$350
   Table 57: European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1121$350
   Table 58: European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1131$350
  15a. FRANCE.......1146 $1950  
   Market Analysis.......114
Table 59: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......114
1$350
   Table 60: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1151$350
   Table 61: French Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1161$350
   Table 62: French Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1171$350
   Table 63: French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1181$350
   Table 64: French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1191$350
  15b. GERMANY.......1206 $1950  
   Market Analysis.......120
Table 65: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......120
1$350
   Table 66: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1211$350
   Table 67: German Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1221$350
   Table 68: German Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1231$350
   Table 69: German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1241$350
   Table 70: German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1251$350
  15c. ITALY.......1266 $1950  
   Market Analysis.......126
Table 71: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......126
1$350
   Table 72: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1271$350
   Table 73: Italian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1281$350
   Table 74: Italian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1291$350
   Table 75: Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1301$350
   Table 76: Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1311$350
  15d. THE UNITED KINGDOM.......1326 $1950  
   Market Analysis.......132
Table 77: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......132
1$350
   Table 78: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1331$350
   Table 79: UK Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1341$350
   Table 80: UK Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1351$350
   Table 81: UK 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1361$350
   Table 82: UK 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1371$350
  15e. SPAIN.......1386 $1950  
   Market Analysis.......138
Table 83: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......138
1$350
   Table 84: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1391$350
   Table 85: Spanish Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1401$350
   Table 86: Spanish Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1411$350
   Table 87: Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1421$350
   Table 88: Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1431$350
  15f. RUSSIA.......1446 $1950  
   Market Analysis.......144
Table 89: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......144
1$350
   Table 90: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1451$350
   Table 91: Russian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1461$350
   Table 92: Russian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1471$350
   Table 93: Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1481$350
   Table 94: Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1491$350
  15g. REST OF EUROPE.......1506 $1950  
   Market Analysis.......150
Table 95: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......150
1$350
   Table 96: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1511$350
   Table 97: Rest of Europe Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1521$350
   Table 98: Rest of Europe Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1531$350
   Table 99: Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1541$350
   Table 100: Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1551$350
  16. ASIA-PACIFIC.......1568 $1950  
   A. Market Analysis.......156
China – Healthcare Reforms to Propel DES Market.......156
Table 101: Coronary Stent Market in China (2010): Percentage Breakdown of Market Share by Company- Shanghai Microport, Beijing Lepu, JW Medical, J&J Cordis, Medtronic and Others (includes corresponding Graph/Chart).......156
1$350
   Coronary Stent Market in a Bubble Zone Now.......157
Regional Players and their DES Development Efforts.......157
Cost Focus Helps Stent Makers Win the Market Stunt.......157
1$100
   B. Market Analytics.......158
Table 102: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......158
1$350
   Table 103: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1591$350
   Table 104: Asia-Pacific Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008(includes corresponding Graph/Chart).......1601$350
   Table 105: Asia-Pacific Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008(includes corresponding Graph/Chart).......1611$350
   Table 106: Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1621$350
   Table 107: Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1631$350
  17. REST OF WORLD.......1647 $1995  
   A. Market Analysis.......164
Brazil – Low Penetration of DES.......164
South Africa – Leading Players.......164
Table 108: Leading Players in South African Coronary Stent Market (2010) – Percentage Breakdown by Unit Sales for Johnson & Johnson, Boston Scientific, Guidant, Abbott and Others (includes corresponding Graph/Chart).......164
1$350
   B. Market Analytics.......165
Table 109: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart).......165
1$350
   Table 110: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart).......1661$350
   Table 111: Rest of World Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart).......1671$350
   Table 112: Rest of World Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart).......1681$350
   Table 113: Rest of World 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1691$350
   Table 114: Rest of World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1701$350
COMPETITION 258$995
  
Total Companies Profiled: 62 (including Divisions/Subsidiaries - 72)

Region/Country                 Players


The United States                 38   
Canada                             1
Japan                              3
Europe                            19
     France                        2
     Germany                       5
     The United Kingdom            1
     Italy                         1
     Spain                         2
     Rest of Europe                8
Asia-Pacific (Excluding Japan)     6
Africa                             2
Middle-East                        3
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign